Research & Development

Research & Development

Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property

CandidateMoleculeDeliveryIndicationDevelopment StatusPartners
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionCommencing Phase IIB trial in H2 CY2022 Monash University MMIC Maquaire University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionCommencing Phase IIB trial in Late CY2022 Monash University MMIC Imperial College London Drug Science (UK)
WP003LSD AnalogueAnxiety, Substance Abuse, PTSDResearch University of Western Australia

WP001 is a low-dose psilocybin drug candidate for treatment of moderate depression. It is being formulated with Monash University’s Medicines Manufacturing Innovation Centre (MMIC, VIC), as a novel rapid-release capsule. A Phase IIB trial is anticipated to commence in H2 CY2022. The trial will be conducted in collaboration with Macquarie University. The trial will enrol over 260 patients with moderate depression in a randomised, controlled study. The primary endpoint will be the Grid-Hamilton Depression Score, with secondary endpoints that include biomarkers, physiological and neurophysiological measures.

Patients interested in the Phase IIB trial of WP001 to treat moderate depression should contact info@wokeph.com


WP002 is a high-dose psilocybin drug candidate with concomitant psychotherapy for treatment of treatment-resistant depression, which is similarly being formulated with MMIC, as a novel rapid release tablet. A Phase IIB trial is anticipated to commence late CY2022 at multiple sites in Australia. This trial is being conducted in collaboration with UK-based Drug Science, led by Professor Dave Nutt at Imperial College London. The trial will enrol approximately 150 patients with treatment-resistant depression in a randomised, controlled study. The primary endpoint will be the MADRS Depression Score, with secondary endpoints that include physiological and neurophysiological measures.

Patients interested in the Phase IIB trial of WP002 to treat treatment-resistant depression should contact info@wokeph.com


WP003 is working with researchers at the University of Western Australia to discover novel analogues of LSD  (lysergic acid diethylamide) for treatment of anxiety, substance abuse and other mental health disorders. Through novel chemistry, Woke Pharmaceuticals aims to enhance the efficacy and solve some of the challenges that have limited the therapeutic application of LSD.